These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25899310)

  • 1. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
    Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
    Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
    Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Alterations in Langerhans Cell Histiocytosis.
    Rollins BJ
    Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
    Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
    Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
    Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
    Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
    Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
    Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.
    Chakraborty R; Burke TM; Hampton OA; Zinn DJ; Lim KP; Abhyankar H; Scull B; Kumar V; Kakkar N; Wheeler DA; Roy A; Poulikakos PI; Merad M; McClain KL; Parsons DW; Allen CE
    Blood; 2016 Nov; 128(21):2533-2537. PubMed ID: 27729324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
    Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
    JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
    McGinnis LM; Nybakken G; Ma L; Arber DA
    Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.
    Kamionek M; Ahmadi Moghaddam P; Sakhdari A; Kovach AE; Welch M; Meng X; Dresser K; Tomaszewicz K; Cosar EF; Mark EJ; Fraire AE; Hutchinson L
    Histopathology; 2016 Sep; 69(3):499-509. PubMed ID: 26915300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
    Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
    Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.